MetaCap

Dianthus Therapeutics (DNTH) vs Ionis Pharmaceuticals (IONS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dianthus Therapeutics (DNTH) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 104.0% versus a loss of 65.1%. Over five years, IONS leads with a -8.5% price change compared with -12.8% for DNTH. Dianthus Therapeutics is the larger company by market cap ($4.76 billion vs $4.43 billion), about 1.1 times the size, while Ionis Pharmaceuticals is growing revenue faster (+33.8% vs -67.3%).

Ionis Pharmaceuticals converts more of its revenue into profit, with a net margin of -40.4% versus -7973.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DNTH+103.98%IONS-65.07%
+192%+57%-77%
Nov 21, 20251 yearNov 20, 2026
DNTH-21.01%IONS-16.91%
+184%+38%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DNTH versus IONS key metrics
MetricDNTHIONS
Share price$84.55$26.58
Market cap$4.76B$4.43B
1-day change-0.33%-2.35%
YTD return+105.17%-66.40%
1-year return+103.98%-65.07%
5-year return-12.80%-8.50%
EPS (TTM)$-4.08$-3.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.04M$943.71M
Revenue growth (YoY)-67.35%+33.83%
Net income (latest FY)$-162.34M$-381.39M
Gross margin—98.31%
Operating margin-8739.34%-40.45%
Net margin-7973.33%-40.41%
52-week high$117.88$86.74
52-week low$35.84$26.53
Distance from 52-week high-28.27%-69.36%
Analyst consensusstrong_buybuy
Avg. price target upside+64.70%+155.19%
Average volume848.96K3.91M
Shares outstanding56.31M166.55M
Employees921,485
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DNTH has outperformed IONS by 169.0 percentage points over the past year.
  • Ionis Pharmaceuticals is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
  • Ionis Pharmaceuticals grew revenue faster in its latest fiscal year (+33.83% vs -67.35%).

About Dianthus Therapeutics

DNTH stock →

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.

Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees

About Ionis Pharmaceuticals

IONS stock →

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).

Health Care · Biotechnology: Pharmaceutical Preparations · 1,485 employees

DNTH vs IONS FAQ

Which is bigger, Dianthus Therapeutics or Ionis Pharmaceuticals?

Dianthus Therapeutics (DNTH) is larger, with a market capitalization of $4.76B compared with $4.43B for Ionis Pharmaceuticals (IONS).

Which stock has performed better over the past year, DNTH or IONS?

DNTH returned +103.98% over the past 12 months, compared with -65.07% for IONS (price return, excluding dividends). Past performance does not predict future results.

Are Dianthus Therapeutics and Ionis Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons